**American College of Surgeons**

**Surgical Critical Care 2013 Update**

**Pulmonary: Physiology, Ventilator-Associated Pneumonia,**

**and Venous Thromboembolism**

**Forrest O. Moore, MD, FACS**

**Director, Trauma & Surgical Critical Care**

**Chandler Regional Medical Center**

**Chandler, AZ**

**PULMONARY PHYSIOLOGY**

I. Lung volumes

 

A. Tidal volume (TV) is the volume of air entering and exiting the lungs during each breath

 1. Approximately 500mL

B. Inspiratory reserve volume (IRV) is the volume of air that can be inhaled (forcibly using inspiratory muscles) beyond normal inspiration (beyond normal TV)

C. Inspiratory capacity (IC) = TV + IRV

D. Expiratory reserve volume (ERV) is the volume of air that can be exhaled (forcibly using expiratory muscles) beyond normal expiration (beyond normal TV)

E. Vital capacity (VC) is the maximum volume of air that can be exhaled forcibly after maximal inspiration (VC = IRV + TV + ERV)

1. Forced vital capacity (FVC) is the total volume expired from maximal inspiration to maximal expiration and is normally 80-120% of the TV

F. Residual volume (RV) is the remaining volume of air that can’t be exhaled forcibly after maximal inspiration (RV = FRC – ERV)

G. Functional residual capacity (FRC) is the volume of air remaining in the lungs after normal passive expiration (FRC = ERV + RV)

1. FRC is the lung’s physiological reserve/reservoir (resting volume of the lung) for gas exchange

 2. Decreased lung compliance reduces FRC 🡪 alveolar collapse

3. Positive end-expiratory pressure (PEEP) is applied at end-expiration and increases FRC by preventing alveolar collapse (atelectrauma)

a. IN ARDS, lung compliance is reduced (lungs are stiffer and more difficult to inflate 🡪 reduction in FRC to a point that is less than closing capacity/volume and results in airway closure 🡪low V/Q 🡪 hypoxemia.

b. PEEP recruits lung units, increases FRC, decreases venous admixture and improves oxygenation

 H. Total lung capacity (TLC) is the volume of air in the lungs after maximal inspiration (TLC = VC + RV)

 I. Minute volume is the volume of air exhaled every minute

J. Forced expiratory volume in 1 second (FEV1) is the volume of air that can be forcefully expired in 1 second

 1. FEV1 = 80% of the VC normally

2. Reduced in obstructive lung disease (increased airway resistance) and in restrictive lung disease (low VC)

K. Spirometry measures TV, IRV, IC, ERV, and VC directly

 1. FVC maneuver (maximal inspiration followed by maximal expiration)

 a. Normal airway resistance = FEV1/FVC > 70%

 b. Obstructive lung disease (asthma, COPD) = ratio decreased

 c. Restrictive lung disease (pulmonary fibrosis) = ratio normal or increased

II. Ventilation (rate at which gas enters and leaves the lungs)

A. Respiratory (minute) ventilation (MV) is the total volume of gas entering the lungs per minute

1. TV (mL/breath) x respiratory rate (RR in breaths/min) = 500mL x 12 = 6L/min of gas/air breathed in and out at rest

B. Dead space ventilation is the volume of gas per unit time that does not reach the alveoli and is not involved in gas exchange but remains in the proximal conducting airways

 1. Dead space (VD) x RR

 2. Dead space = 0.15L (volume in conducting airways is anatomic dead space)

 3. 1.8L/min at rest

C. Alveolar ventilation is the volume of gas per unit time that reaches the alveoli (where gas exchange occurs)

 1. (TV – VD) x RR = (500mL – 150mL) x 12 breaths/min = 4.2L/min at rest

 2. Increasing TV (slow and deep breaths) is more efficient method to increase alveolar ventilation as increasing RR (fast and shallow) increases alveolar ventilation as well, but also increases dead space

 a. In ALI/ARDS, tidal volumes of 6 mL/kg result in significant atelectasis leading to wasted ventilation 🡪 increase RR to control PaCO2

III. Gas exchange

A. Primary purpose of the respiratory system is to exchange oxygen and carbon dioxide across the alveolar epithelium and capillary endothelium via passive diffusion

 1. Rate of gas transfer dependent on:

a. The difference in partial pressure of the gases across the membrane

b. The surface area of the membrane

c. The thickness of the membrane

d. The molecular weight and the solubility of the gas crossing the membrane

 aa. CO2 is 20X more soluble than O2



 B. Efficiency of gas exchange across the lung calculated using alveolar gas equation

 1. The partial pressure of CO2 in arterial blood (PaCO2) increases when minute ventilation decreases 🡪 decreases alveolar PAO2 and arterial PaO2 because CO2 displaces oxygen in the alveolus

 2. PAO2 = FIO2 x (Patm – PH2O) – (PaCO2/RQ) where RQ = the respiratory quotient (O2 consumed to CO2 produced when nutrients are metabolized) and varies from 0.7-1.0 (1.0 carbohydrate, 0.7 protein, and 0.6 fat)

 = 0.21 x (760 mm Hg – 47 mm Hg) – (40 mm Hg/0.8)

 = 100 to 110 mm Hg

 C. Dead space

 1. Alveolar dead space is when air contacts the alveoli but lack blood flow in adjacent pulmonary capillaries (ventilation without perfusion as in PE) and therefore no gas exchange

 2. Physiologic dead space = anatomic dead space + alveolar dead space

 a. Wasted portion of breath that does not participate in CO2 exchange



 b. PE, pulmonary vasoconstriction, and high tidal volume ventilation act to increase physiologic dead space

 c. With lung disease, dead space varies compared to tidal volume. VD/VT ratio helps determine how much respiratory effort is being wasted

 aa. normal ratio is 0.15 to 0.35

 bb. in critically ill, may exceed 0.7 (70% is wasted ventilation)

 D. Diffusing capacity of the lung for carbon monoxide (DLCO) – volume of CO transferred across the alveolar-capillary membrane (ease with which oxygen moves from inhaled air to the RBC in the pulmonary capillaries) per minute per unit alveolar partial pressure. Normal 17- 25 mL/min/mmHg

 1. Decreased in COPD; normal or high in asthma

IV. Lung zones and V/Q

 A. Zones reflect influence of gravity on degree of alveolar distention and blood flow

 1. in the upright position (standing), Zone 1 is at the apices, Zone 3 at the bases

 2. in the supine position, Zone 1 is the most anterior, Zone 3 is most posterior

 3. PA = Alveolar pressure. Pa = arterial pressure. Pv = venous pressure.

1. **Zone 1: PA > Pa > Pv.**

Gravity stretches the Zone 1 alveoli most; negative pressure created by inspiration is greatest in Zone 1; distention of alveoli (and therefore alveolar pressure) greatest in Zone 1. Theoretically with maximal alveolar distention, alveolar pressure would be greater than arterial pressure and therefore prevent blood flow. Likely occurs more in the hypovolemic state rather than in normal euvolemic lungs. Ventilation (V) is highest and perfusion (Q) is lowest in Zone 1, so V/Q ratio is highest here.

b. **Zone 2: Pa > PA > Pv.**

Arterial pressure overcomes alveolar pressure, allowing blood flow, but with distention alveolar pressure still higher than venous pressure and may inhibit flow. Ventilation and perfusion are best matched in Zone 2.

c. **Zone 3: Pa > Pv > PA.**

Perfusion is greatest but ventilation poorest in Zone 3, so V/Q ratio is lowest here. Zone 3 affects gas exchange most, as it is more dependent on blood flow.

4. Manipulation of the lung zones is the basis of rotational therapy for mechanically ventilated patients and for prone positioning of ARDS patients. By shifting Zones 1 and 3 back and forth, overall V/Q mismatch is decreased, and gas exchange is improved.

B. V/Q mismatch

1. V/Q mismatch described in terms of the “A-a gradient”: the difference in partial pressure of oxygen between the Alveoli (A) and arterial blood (a).

 a. Anatomic shunt (AKA true shunt)

aa. - 3-5% of blood reaching the left heart has not gone through the pulmonary capillary circulation (i.e. anatomic shunt)

 - bronchial blood flow

 - thebesian veins going directly to left heart

bb. - because of the anatomic shunt the paO2 of normal arterial blood (breathing room air) is reduced from about 100 mmHg in the pulmonary veins to about 95 mmHg after leaving the heart

b. In Zone 1 (high V/Q, lower blood flow so more opportunity for gas exchange), paO2 of blood leaving alveoli is > 100 mmHg, while in Zone 3 (low V/Q, higher blood flow but less ventilation), paO2 is < 100 mmHg

2. PA calculated by the alveolar gas equation:

 PAO2 = (FIO2 x [Patmos – P H2O]) – (PaCO2 / RQ)

 FIO2 = fraction of inspired oxygen

 Patmos = atmospheric pressure, i.e. 760 mm Hg at sea level

 P H2O = water vapor pressure at 37 degrees, i.e. 47 mm Hg

 PaCO2 = partial pressure of arterial CO2

RQ = respiratory quotient, i.e. ratio of CO2 eliminated to O2 consumed, which is normally 0.8

C. Shunt

1. Anatomic shunt - discussed in IV.B.1.a.

 2. Transpulmonary shunt

a. shunting of blood through the pulmonary circulation without first being oxygenated (or being suboptimally oxygenated)

b. occurs with perfusion of nonventilated or hypoventilated alveoli (e.g. infection, pulmonary edema, atelectasis), or by inability of O2 to diffuse across the alveolar membrane into the blood (e.g. interstitial fibrosis)

c. shunted blood is not further oxygenated, mixes with the remaining pulmonary circulation and lowers the overall paO2 (i.e. hypoxemia)

 d. degree of shunting calculated by the shunt fraction (Qs/Qt)

 Qs/Qt = CcO2 – CaO2

 CcO2 – CvO2

CcO2 = O2 content in pulmonary capillary blood (i.e. just post-alveolus and maximally oxygenated)

CaO2 = O2 content in arterial blood (i.e. after leaving the heart, so includes blood from the anatomic shunt whose O2 content is normally a bit lower than the CcO2, and from the transpulmonary [pathological] shunt)

 CvO2 = O2 content in venous blood

e. CcO2 not directly measurable clinically, so shunt fraction can be estimated from existing graphs

f. the normal shunt fraction is < 10%

V. Oxygen Transport

A. Oxygen delivery

1. Oxygen delivery (DO2) = the rate of blood flow (cardiac output) x O2 content of blood

 = CO x CaO2

 = CO x 10 x (Hgb x 1.34 x O2 sat) + 0.003(paO2)

 Where: CO is in liters/minute

 Hgb is hemoglobin in g/dL

 1.34 is the amount of O2 in mL per g of Hgb

 O2 saturation is in decimal form (98% = 0.98)

 0.003 is the amount of O2 dissolved in plasma,

 i.e. 0.003 mLO2 per dL plasma, per mmHg paO2

 10 is the conversion factor to put the result in mL/minute

 a. Dissolved amount of O2 is negligible, and can be omitted for general use

 aa. this is why paO2 is not clinically relevant to tissue oxygenation

 bb. interventions/ventilator adjustments should not be done to "treat" paO2

 cc. paO2 is only a measure of efficiency of gas exchange by the lungs

 b. Equation abbreviated to **DO2 = CO x 10 x Hgb x 1.34 x O2sat**

 aa. normal CaO2 = 20mL/dL

 bb. DO2 with CO of 5L/min = 5 x 10 x 20 = 1000mL/min

 B. O2/Hgb dissociation curve

1. A graphical plot of the oxygen saturation of Hgb (y axis) to oxygen tension/paO2 (x axis)

 a. Sigmoid shaped curve

 aa. memory device: "90-60, 60-30, 75-40"

 bb. each 1st number is O2 sat, 2nd is paO2, so a 90% sat corresponds to a paO2 of 60 mmHg

 2. Curve shifts - certain factors increase or decrease hemoglobin's affinity for O2

a. Rightward shift - decreased affinity for O2; oxygen is released more easily to tissues

 aa. need higher paO2 to get same O2 sat;

 bb. think "Right-Release"

 cc. increases in temperature, acidosis, and 2,3-DPG shift curve to right

dd. think of exercise: body heats up, produces acid (lactate), so curve shifts to right to release more O2 to tissues

 b. Leftward shift - increased affinity for O2; oxygen more tightly bound

 aa. decreased temperature and 2,3-DPG, and alkalosis shift curve to left

 bb. alkalosis worse for tissue oxygenation based on the curve shift (less offloading of 02 to tissues)

**VENTILATOR-ASSOCIATED PNEUMONIA**

I. Diagnostic strategies

 A. Clinical

 1. Signs of infection

 a. Fever/hypothermia

 b. Leukocytosis/leucopenia

 c. Purulent sputum

 d. Decline in oxygenation

 2. CXR

 a. New or progressing lung infiltrate

 B. Bacteriologic

 1. Quantitative cultures of the lower respiratory tract

 a. Sputum culture

 b. Bronchoalveolar lavage

 c. Protected specimen brush

 2. Growth above set threshold = VAP

 C. Limitations

 D. Controversies

II. VAP definition

 A. NHSN – no reliable, valid definition

 1. 2002 definition designed for surveillance of all healthcare-associated PNA events and not limited to VAP

 2. PNA that occurs at the time a ventilator is in place, or within 48 hours after a ventilator has been in place

 a. ***No required duration for the ventilator to qualify as a VAP***

 3. Surveillance and prevention practices difficult to track

 B. Elements

 1. CXR

 2. Clinical signs/symptoms

 3. Microbiology

 C. Decline in VAP rates

 1. Evidence-based prevention

 2. Lowering VAP rates without improving patient care

 D. CDC VAP Surveillance Definition Working Group

 1. Tasked with developing a valid and reliable definition of VAP

 2. Improve accuracy of reporting HAIs

 3. Comparison among facilities

 4. Pay-for-performance

III. Ventilator-associated events (VAEs)

 A. Tiers 1 and 2

 1. Potential use for public reporting

 B. Tier 3

 1. Internal use for quality improvement

 2. Possible VAP/probable VAP

 C. Ventilator-associated condition (VAC)

 D. Infection-related ventilator-associated complication (IVAC)

 E. Possible or probable VAP

IV. VAP bundle

 A. Reduce complications by improving quality of care

 B. Bundle components

 1. Daily SBT

 2. Daily sedation holiday

 3. Stress gastritis prophylaxis

 4. Elevation of head of bed

 5. DVT prophylaxis

 6. Daily oral care

 C. Additional evidence-based components

 1. Restrictive blood transfusion

 2. Use of NIPPV

 3. Continuous aspiration of subglottic secretions

 4. Strict glycemic control

 5. Early tracheostomy for select groups of patients

V. Treatment

 A. Duration

 1. Non-fermenting gram negative rods: higher recurrence with 8 days of treatment

 2. Magnotti et al.

**VENOUS THROMBOEMBOLISM**

I. Epidemiology

 A. PE remains the most common preventable cause of in-hospital mortality

 B. AHRQ - #1 strategy to improve patient safety in hospitals is prevention of VTE

II. Incidence

III. IVCFs

 A. Not recommended as primary prophylaxis according to the 2008 and 2012 ACCP guidelines as noted in CHEST

 B. 2002 EAST guidelines

 1. Level III evidence

 a. Prophylactic placement in very high risk trauma patients who are unable to receive chemoprophylaxis

 C. Retrievable

 1. Lack of high quality data to support use

IV. Chemical prophylaxis

 A. LDUH

 1. Heparin 5000 U’s SQ TID may be as effective as enoxaparin in trauma patients

 2. Low quality evidence in trauma patients

 B. Fondaparinux

 1. No HIT

 2. No antidote

 C. VKA

 D. DTIs

 E. Oral agents

 1. Rivaroxaban

 2. Dabigatran

 3. ASA

 a. Low quality evidence in favor of use when contraindication to LMWH or UFH in high risk patients undergoing major general or abdominopelvic surgery

V. Traumatic brain injury

 A. LMWH vs. LDUH

 B. Brain Trauma Foundation recommendations (2007)

 1. Insufficient evidence to support preferred agent, dose, or timing

 C. DEEP I study

 1. Low risk TBI patients with progression rates equal to placebo after starting enoxaparin at 24 hours after injury

**REFERENCES**

1. Klompas M. Eight initiatives that misleadingly lower ventilator-associated pneumonia rates. *Am J Infect Control*. 2012;40(5):408-10.

2. Klompas M. Ventilator-associated events surveillance: a patient safety opportunity. Curr Opin Crit Care. 2013 Jun 17 [Epub ahead of print]

3. Craven DE. Preventing ventilator-associated pneumonia in adults: sowing seeds of change. *Chest*. 2006;130(1):251-60.

4. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. *Am J Respir Crit Care Med*. 2005;171(4):388-416.

5. Barquist ES, Amortegui J, Hallal A, Giannotti G, Whinney R, Alzamel H, MacLeod J. Tracheostomy in ventilator dependent trauma patients: a prospective, randomized intention-to-treat study. *J Trauma*. 2006;60(1)91-7.

6. Griffiths J, Barber VS, Morgan L, Young JD. Systematic review and meta-analysis of studies of the timing of tracheostomy in adult patients underoing artificial ventilation. *BMJ*. 2005;330(7502):1243-7.

7. Young D, Harrison DA, Cuthbertson BH, Rowan K; TracMan Collaborators. Effect of early vs. late tracheostomy placement on survival in patients receiving mechanical ventilation: the TracMan randomized trial. *JAMA*. 2013;309(20):2121-9.

8. Gomes SBN, Andriolo RB, Saconato H, Atallah AN, Valente O. Early versus late tracheostomy for critically ill patients. *Cochrane Database Syst Rev*. 2012 Mar 14;3:CD007271.

9. Rizk EB, Patel AS, Stetter CM, Chinchilli VM, Cockroft KM. Impact of tracheostomy timing on outcome after severe head injury. *Neurocrit Care*. 2011;15(3):481-9.

10. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S; PneumA Trial Group. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. *JAMA*. 2003;290(19):2588-98.

11. Fekih Hassen M, Ayed S, Ben Sik Ali H, Gharbi R, Marghli S, Elatrous S. Duration of antibiotic therapy for ventilator-associated pneumonia: comparison of 7 and 10 days. A pilot study. *Ann Fr Anesth Reanim*. 2009;28(1):16-23.

12. Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK. Short-versus long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. *Chest*. 2013 June 20 [Epub ahead of print].

13. Magnotti LJ, Croce MA, Zarzaur BL, Swanson JM, Wood GC, Weinberg JA, Fabian TC. Causative pathogen dictates optimal duration of antimicrobial therapy for ventilator-associated pneumonia in trauma patients. *J Am Coll Surg*. 2011;212(4):476-84.

14. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM; American College of Chest Physicians. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl)e227S-77S.

15. Rogers FB, Cipolle MD, Velmahos G, Rozycki G, Luchette FA. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group. J Trauma. 2002;5391);142-64.

16. O’Keeffe T, Thekkumel JJ, Friese S, Shafi S, Josephs SC. A policy of dedicated follow-up improves the rate of removal of retrievable inferior vena cava filters in trauma patients. *Am Surg*. 2011;77(1):103-8.

17. Rogers FB, Shackford SR, Miller JA, Wu d, Rogers A, Gambler A. Improved recovery of prophylactic inferior vena cava filters in trauma patients; the results of a dedicated filter registry and critical pathway for filter removal. *J Trauma Acute Care Surg*. 2012;72(2):381-4.

18. Arnold JD, Dart BW, Barker DE, Maxwell RA, Burkholder HC, Mejia VA, Smith PW, Longley JM. Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients. *Am Surg*. 2010;76(6):563-70.

19. Phelan HA, Wolf SE, Norwood SH, Aldy K, Brakenridge SC, Eastman AL, Madden CJ, Nakonezny PA, Yang L, Chason DP, Arbique GM, Berne J, Minei JP. A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: The Delayed Versus Early Enoxaparin Prophylaxis I (DEEP I) Study. *J Trauma Acute Care Surg*. 2012;73(6):1434-41.